大行评级｜招银国际：上调信达生物目标价至102.95港元看好其丰富的创新管线

格隆汇2025-07-08

招银国际发表研究报告指出，信达生物旗下IBI363(PD-1/IL-2)具显著的存活益处和巨大潜力，有望成为重磅级下一代免疫疗法，尤其适用于免疫耐受性和冷肿瘤，目前正在进行第三阶段临床试验。除IBI363外，信达生物正打造强大的下一代免疫肿瘤(IO)药物和抗体药物偶联物(ADC)的产品组合，并在IO-ADC联合治疗策略领域处于前沿，是未来肿瘤药物开发的关键趋势。此外，信达生物亦正开发多款创新免疫...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2549596551?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-08 11:46","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2549596551","market":"hk","top_or_hot":-1,"title":"大行评级｜招银国际：上调信达生物目标价至102.95港元 看好其丰富的创新管线","media":"格隆汇","content":"<div>\n<p>招银国际发表研究报告指出，信达生物旗下IBI363(PD-1/IL-2)具显著的存活益处和巨大潜力，有望成为重磅级下一代免疫疗法，尤其适用于免疫耐受性和冷肿瘤，目前正在进行第三阶段临床试验。除IBI363外，信达生物正打造强大的下一代免疫肿瘤(IO)药物和抗体药物偶联物(ADC)的产品组合，并在IO-ADC联合治疗策略领域处于前沿，是未来肿瘤药物开发的关键趋势。此外，信达生物亦正开发多款创新免疫...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n","source":"live_gelonghui","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>大行评级｜招银国际：上调信达生物目标价至102.95港元 看好其丰富的创新管线</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n大行评级｜招银国际：上调信达生物目标价至102.95港元 看好其丰富的创新管线\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-08 11:46 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/rss/live/live.xml><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>招银国际发表研究报告指出，信达生物旗下IBI363(PD-1/IL-2)具显著的存活益处和巨大潜力，有望成为重磅级下一代免疫疗法，尤其适用于免疫耐受性和冷肿瘤，目前正在进行第三阶段临床试验。除IBI363外，信达生物正打造强大的下一代免疫肿瘤(IO)药物和抗体药物偶联物(ADC)的产品组合，并在IO-ADC联合治疗策略领域处于前沿，是未来肿瘤药物开发的关键趋势。此外，信达生物亦正开发多款创新免疫...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADC.AU","symbol_name":"ACDC Metals Ltd","start_time":0,"source_url":"https://www.gelonghui.com/rss/live/live.xml","article_id":"2549596551","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549596551","pubTimestamp":1751946396,"columns":[],"sourceInfo":{"source_id":"live_gelonghui","name":"格隆汇"},"weMediaInfo":null,"summary":"招银国际发表研究报告指出，信达生物旗下IBI363(PD-1/IL-2)具显著的存活益处和巨大潜力，有望成为重磅级下一代免疫疗法，尤其适用于免疫耐受性和冷肿瘤，目前正在进行第三阶段临床试验。除IBI3","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ADC.AU":"ACDC Metals Ltd","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1583":"高瓴概念","BK7095":"多种金属与采矿","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托","03347":"泰格医药","01801":"信达生物","BK1589":"北水核心资产","ADC":"艾格里房产","GLP":"Global Partners Lp","PD":"PagerDuty, Inc.","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1576":"医药外包概念","BK1141":"生命科学工具和服务","BK1161":"生物科技","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4023":"应用软件","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4144":"石油与天然气的储存和运输","BK4590":"PTP"},"translate_title":"Big Bank Ratings | CMB International: Raised Innovent Biologics' target price to HK $102.95, optimistic about its rich innovation pipeline","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLP":1,"PD":1,"01801":1,"ADC.AU":1,"03347":1,"ADC":1},"content_text":"招银国际发表研究报告指出，信达生物旗下IBI363(PD-1/IL-2)具显著的存活益处和巨大潜力，有望成为重磅级下一代免疫疗法，尤其适用于免疫耐受性和冷肿瘤，目前正在进行第三阶段临床试验。除IBI363外，信达生物正打造强大的下一代免疫肿瘤(IO)药物和抗体药物偶联物(ADC)的产品组合，并在IO-ADC联合治疗策略领域处于前沿，是未来肿瘤药物开发的关键趋势。此外，信达生物亦正开发多款创新免疫肿瘤药物，包括PD-1/IL-12、PD-L1/CD40，以及多个靶向GPRC5D/BCMA/CD3、DLL3/CD3和CLDN18.2/CD3的靶向T细胞衔接器(TCE)等。另外，公司最近推出玛仕度肽(Mazdutide)，是中国首款国产双标靶GLP-1肥胖症治疗药物，标志着其非肿瘤药物组合中的重大里程碑。\n招银国际对信达生物丰富的创新管线以及其在全球的潜力持乐观态度，认为公司有望在今年实现EBITDA收支平衡。该行将信达生物目标价从94.74港元上调至102.95港元，维持“买入”评级。","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2549596551","isCrawlerRequest":true}

大行评级｜招银国际：上调信达生物目标价至102.95港元 看好其丰富的创新管线

精彩评论

大行评级｜招银国际：上调信达生物目标价至102.95港元看好其丰富的创新管线